Fast Restoration of a Broad-Spectrum SARS-Cov Therapeutic Antibody for SARS-Cov-2
2020
The
rapid spread of SARS-Cov-2 remains a major threat for public health and global
economy, both preventative and therapeutic solutions are therefore urgently
needed. Through the use of epitope-guided antibody design, we successfully
restored a broad-spectrum SARS-Cov therapeutic antibody for SARS-Cov-2. Compared
to the precursor antibody CR3022, the newly designed antibody NOVOAB-20 binds
to SARS-Cov-2 receptor binding domain (RBD) with a more than 10-fold higher
affinity. Because this antibody targets
a highly conserved epitope and the mutations on
SARS-Cov-2 known so far are all not in this region, it also has the
potential to block future SARS-Cov-2 mutants. As a fully humanized antibody,
NOVOAB-20 is a promising candidate to be developed as potential therapeutics
for SARS-Cov-2, either as monotherapy or in combination with other neutralizing
antibodies targeting different epitopes (e.g. the ACE2 binding site). This fast
antibody restoration rationale may also be useful for designing drugs for other
pandemic-causing viruses.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI